Usage: Geftistar (gefitinib) is an oral medication classified as an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI). It is prescribed for the treatment of non-small cell lung cancer (NSCLC), specifically in patients whose tumors harbor certain mutations in the epidermal growth factor receptor (EGFR) gene.

Mechanism of Action: Gefitinib works by inhibiting the tyrosine kinase activity of the EGFR. This action interferes with the signaling pathways that promote the growth and survival of cancer cells. It is particularly effective in tumors with specific EGFR mutations.

Dosage and Administration: The dosage of Geftistar is determined by a healthcare professional based on individual patient factors, the specific EGFR mutation present, and the overall health status. It is taken orally, usually once a day, with or without food.

Genetic Testing: Patients with NSCLC are often tested for EGFR mutations to determine whether they are eligible for treatment with gefitinib. This testing helps identify individuals who are more likely to respond positively to the medication.

Monitoring and Adjustments: Patients taking Geftistar may undergo regular medical monitoring, including imaging scans and laboratory tests, to assess the response to treatment and manage potential side effects. Dosage adjustments or changes in the treatment plan may be made based on the individual’s response.

Side Effects: Common side effects of gefitinib may include skin rash, diarrhea, nausea, and changes in liver function tests. Serious side effects, though less common, can include interstitial lung disease, liver problems, and gastrointestinal perforations. It’s important for patients to report any unusual or severe side effects to their healthcare provider.

Precautions: Before starting Geftistar, patients should inform their healthcare provider about their medical history, current medications, and any pre-existing conditions. Certain medications, especially those affecting liver function, may interact with gefitinib.

Conclusion: Geftistar (gefitinib) is a targeted therapy used in the treatment of non-small cell lung cancer with specific EGFR mutations. Its mechanism of action involves inhibiting EGFR tyrosine kinase activity to impede cancer cell growth. Patients prescribed Geftistar should closely follow their healthcare provider’s instructions and report any concerns or side effects promptly.